|
Eli Lilly News is an EIN News Service for health professionals. Constantly updated news and information about health.
- PRIMECAP Management Top Purchases: AMGN, BA, ERIC, ERTS, LLY 24 Nov 2009 05:17 GMT
... shares were traded at around $17.3 with and P/S ratio of 1.4. No. 5: Eli Lilly and Company ( ), Add: 0.12% of the portfolio - Total: 62,428,802 Shares Eli ...
- Science vs. business: Who makes a... 24 Nov 2009 11:10 GMT
... reports to Daniel Vasella, also a physician and CEO of Novartis. Surprisingly, at present, Eli Lilly is the only major pharmaceutical company that hired a Ph.D. as its CEO. John ...
- ASTMH Symposium Showcases Efforts To Meet The Need For New Medicines To Treat Infectious Diseases In Developing Countries 24 Nov 2009 15:21 GMT
... Pharma -- Jorg J. Mohrle, Medicines for Malaria Venture, Geneva, Switzerland Extending a Hand: Eli Lilly's TB Drug Discovery Partnership -- Gail H. Cassell, Eli Lilly & Co., Indianapolis, IN ...
- New Pharmaceuticals Antidepressants research report from Datamonitor 24 Nov 2009 16:31 GMT
... the launch of Remeron (mirtazapine; Schering Plough), Lexapro (escitalopram; Lundbeck and Mochida), Cymbalta (duloxetine; Eli Lilly and Shionogi) and Pristiq (desvenlafaxine; Wyeth). Eli Lilly's efforts to gain a broad range ...
- Hewlett-Packard Fourth-Quarter PC Sales Top Estimates 24 Nov 2009 00:15 GMT
... earlier. Hewlett-Packard signed new services contracts with customers including Coca-Cola Co., Alcatel-Lucent SA, and Eli Lilly & Co., Hurd said. “A story within the story with services was the strength ...
- Make money, make a difference with the power of crowdsourcing 24 Nov 2009 01:30 GMT
... offered range from $1,000 to $1 million. Seeker organizations include corporate giants Avery Dennison, Eli Lilly, Janssen, Procter & Gamble and Solvay, while non-profit Seekers include the Rockefeller Foundation, GlobalGiving, ...
- Pfizer may join Japanese generics market in 2011 24 Nov 2009 04:31 GMT
... lose patent protection in by 2012, including products made by GSK, AstraZeneca, Novartis and Eli Lilly. The authors argue that this, coupled with likely support for greater generic use from ...
- Derrick Z. Jackson: Drug firms dance to same old song on health reform 24 Nov 2009 08:22 GMT
... Street Journal story, Credit Suisse analyst Catherine Arnold detailed how Bristol-Myers Squibb, Pfizer and Eli Lilly raised the prices of leukemia, kidney cancer, attention deficit and erectile dysfunction drugs by ...
- Clinical Trials in Russia. 3rd Quarter 2009 24 Nov 2009 09:50 GMT
... new studies, and Merck & Co. with four. The top five is concluded by Eli Lilly having four new studies and fewer patients in Q3 2009. The Russian pharmaceutical company ...
- U.S. Court rules in Merck's favor in Flemings case involving FOSAMAX 24 Nov 2009 10:27 GMT
... Adams County boy died on Oct. 31 as a ... Amylin Pharmaceuticals, Inc., and Eli Lilly and Company today issued the following statement in resp... The U.S. Department of Justice, ...
- Norway's Clavis signs $380 million deal with Clovis 24 Nov 2009 11:16 GMT
... Norway’s Clavis signs $380 million deal with Clovis Norwegian drugmaker Clavis Pharma has signed a ...
- Artel to Launch New Technology at LabAutomation2010 24 Nov 2009 14:12 GMT
... Leading institutions such as Amgen, ARUP, Bristol-Myers Squibb, Celgene, Centers for Disease Control, DuPont, Eli Lilly, FBI, Genentech, Genomic Health, Mayo Clinic, Memorial Sloan-Kettering Cancer Center, Merck, Pfizer, Procter & ...
- Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 24 Nov 2009 18:30 GMT
... Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis. Effient is a trademark of Eli Lilly and Company. CONTACT: Megan Rusnack Lippert/Heilshorn & Associates 212-838-3777 mrusnack@lhai.com Timothy I. Still President ...
- Clavis, Clovis in Potential $380M Deal on Pancreatic Cancer Drug 24 Nov 2009 23:26 GMT
... bypasses a resistance mechanism that affects the efficacy of gemcitabine, marketed as Gemzar by Eli Lilly and Co., of Indianapolis. Its lipid tail enables the compound to diffuse passively across ...
- No Better Survival at High-Volume PCI Centers 24 Nov 2009 23:26 GMT
... interest with AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Heartscape, sanofi-aventis, The Medicines Company, Centocor, Daiichi-Sankyo, Eli Lilly, GlaxoSmithKline, Millennium, Paringenix, PDL, Schering-Plough, Arena, Astellas, Bayer, Cardax, Johnson & Johnson, McNeil, Medtronic, ...
Powered by 
These stories are not published by IPD Group, Inc. and these links will take you to other websites. Some of these websites require their own registration to read their stories.
<<< Please read the disclaimer for more details.>>> | |
Healthcare Industry Today
|
a digital news provider
nytimes.com:
ap.org:
bbc.co.uk:
reuters.com:
msnbc.msn.com:
healthday.com: